Related references
Note: Only part of the references are listed.The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
Asish K. Ghosh et al.
BLOOD (2011)
Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA
Mark Mackiewicz et al.
BREAST CANCER RESEARCH AND TREATMENT (2011)
Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer
G. Mudduluru et al.
ONCOGENE (2011)
Epigenetic inactivation of the miR-34a in hematological malignancies
C. S. Chim et al.
CARCINOGENESIS (2010)
The miR-34 family in cancer and apoptosis
H. Hermeking
CELL DEATH AND DIFFERENTIATION (2010)
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Thorsten Zenz et al.
BLOOD (2009)
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Thorsten Zenz et al.
BLOOD (2009)
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
M. K. Dijkstra et al.
LEUKEMIA (2009)
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Dmitri Lodygin et al.
CELL CYCLE (2008)
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Tsung-Cheng Chang et al.
MOLECULAR CELL (2007)
The role of prognostic factors in assessing 'high-risk' subgroups of patients with chronic lymphocytic leukemia
N. E. Kay et al.
LEUKEMIA (2007)
Chk2 is a tumor suppressor that regulates apoptosis in both an ataxia telangiectasia mutated (ATM)-dependent and an ATM-independent manner
A Hirao et al.
MOLECULAR AND CELLULAR BIOLOGY (2002)
Share Paper
